BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
1.050
-0.020 (-1.87%)
At close: Sep 25, 2026, 4:00 PM EDT
1.070
+0.020 (1.90%)
After-hours: Sep 25, 2026, 7:22 PM EDT
BioCardia Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
15.90M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 58.00K | -419.00K | -87.84% |
| Dec 31, 2023 | 477.00K | -875.00K | -64.72% |
| Dec 31, 2022 | 1.35M | 337.00K | 33.20% |
| Dec 31, 2021 | 1.02M | 870.00K | 600.00% |
| Dec 31, 2020 | 145.00K | -565.00K | -79.58% |
| Dec 31, 2019 | 710.00K | 85.00K | 13.60% |
| Dec 31, 2018 | 625.00K | 146.00K | 30.48% |
| Dec 31, 2017 | 479.00K | -97.00K | -16.84% |
| Dec 31, 2016 | 576.00K | -328.00K | -36.28% |
| Dec 31, 2015 | 904.00K | 477.00K | 111.71% |
| Dec 31, 2014 | 427.00K | 159.00K | 59.33% |
| Dec 31, 2013 | 268.00K | 206.00K | 332.26% |
| Dec 31, 2012 | 62.00K | 50.00K | 416.67% |
| Dec 31, 2011 | 12.00K | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 1.27M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 12.88M |
| Cerenome | 4.20M |
| Dyadic International | 3.80M |
| Allarity Therapeutics | 345.00K |
| Kiora Pharmaceuticals | 20.00K |
BCDA News
- 4 days ago - BioCardia provides update on near term milestones for CardiAMP, Helix - TheFly
- 4 days ago - BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission - GlobeNewsWire
- 17 days ago - BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 4 weeks ago - BioCardia gets FDA confirmation of Helix meeting minutes - TheFly
- 4 weeks ago - BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval - GlobeNewsWire
- 6 weeks ago - BioCardia Earnings Call Transcript: Q2 2026 - Transcripts
- 6 weeks ago - BioCardia Quarterly report: Q2 2026 - Filings
- 6 weeks ago - BioCardia Earnings release: Q2 2026 - Filings